Assignee
ARSTAT INC
US·12 granted patents·7 pending applications·5 citations·filing 2013–2022
Top patents by PatentIndex Score
19 records- 0187US11116718B2Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agentARSTAT INC·Filed 2019·Granted Sep 14, 2021·2 cites·6 claims
- 0285US10251836B2Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agentARSTAT INC·Filed 2013·Granted Apr 9, 2019·3 cites·8 claims
- 0380US11833126B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2022·Granted Dec 5, 2023·0 cites·13 claims
- 0478US11103515B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2019·Granted Aug 31, 2021·0 cites·12 claims
- 0577US10709679B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2019·Granted Jul 14, 2020·0 cites·13 claims
- 0672US11351132B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2020·Granted Jun 7, 2022·0 cites·13 claims
- 0770US10537582B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2019·Granted Jan 21, 2020·0 cites·12 claims
- 0868US10463678B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2018·Granted Nov 5, 2019·0 cites·6 claims
- 0967US10532037B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2019·Granted Jan 14, 2020·0 cites·13 claims
- 1067US10111887B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2018·Granted Oct 30, 2018·0 cites·12 claims
- 1165US9675622B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2014·Granted Jun 13, 2017·0 cites·12 claims
- 1264US9925199B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2017·Granted Mar 27, 2018·0 cites·12 claims
- 1361US2019201418A1Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agentARSTAT INC·Filed 2019·Application pending·0 cites
- 1460US2014039054A1Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2013·Application pending·0 cites
- 1559US2014005157A1Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestationalARSTAT INC·Filed 2013·Application pending·0 cites
- 1659US2013345678A1Treatment of excessive menstrual blood loss by feminine sanitary products medicated with antifibrinolytic or hemostatic agentARSTAT INC·Filed 2013·Application pending·0 cites
- 1753US2019151634A1Treatment of excessive menstrual blood loss by feminine sanitary products medicated with hemostatic agentARSTAT INC·Filed 2019·Application pending·0 cites
- 1850US2014030313A1Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drugARSTAT INC·Filed 2013·Application pending·0 cites
- 1950US2013337054A1Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibrinolytic or hemostatic agentARSTAT INC·Filed 2013·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →